The new HTA guides 2017 could be up to their predecessors

From the first reports, back in 1920, we have studied, recognized and documented the excess of events associated with arterial hypertension. This linear relationship between the level of blood pressure and the risk of stroke, is evident in all adults beyond age, sex or race, transforming high blood pressure into the highest target of global public health.

Las nuevas guías Europeas de Hipertensión contrastan con las Americanas

The greatest impact of reducing hypertension was observed in adults between 60 and 74 years, where a decrease in systolic pressure from 148 to 129 mm Hg led to a 50% reduction in stroke risk, and a decrease from 188 to 156 mm Hg to a reduction of 90% of the risk!


Read also: New High Blood Pressure Guidelines.


These lower levels of blood pressure observed were, obviously, thanks to the pharmacological treatment of this age group. However, lower levels were also observed in the group between 20 and 29 years, which suggests that prevention and non-pharmacological treatment are also very effective.

From the end of the 90s until 2017, the evidence from randomized clinical studies and epidemiological studies was incorporated into the guidelines to detect, treat, control and prevent hypertension in the most effective way possible.

With each new guide that redefined objectives and improved treatment protocols, a decrease in the population’s blood pressure and a reduction in stroke risk was observed. These improvements cannot be attributed to the guidelines themselves, but rather to the implementation by doctors of their recommendations in daily clinical practice.


Read also: Patients with Resistant Hypertension: Nearly 50% doesn’t take medication.


The reduction in the risk of stroke due to the decrease in blood pressure has been proposed as the greatest achievement of public health in the last 50 years. This achievement is not more than the result of the application in daily clinical practice of recommendations based on evidence and adherence to treatment by patients.

We hope that the ambitious recommendations of the new hypertension guidelines of 2017 can continue with the trend of their predecessors, since there is still a huge potential in improving the cerebrovascular health of the population.

Original title: Implications of New High Blood Pressure Guidelines for Stroke Primary and Secondary Prevention.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | SIRONA: Randomized Study Comparing Sirolimus-Coated vs Paclitaxel-Coated Balloon Angioplasty in Femoropopliteal Disease

This prospective, randomized, multicenter, investigator-initiated non-inferiority study compared the use of sirolimus-coated balloon (MagicTouch) vs paclitaxel-coated balloon in endovascular treatment.  The primary objective was to...

TCT 2024 | PEERLESS: Mechanical Thrombectomy with FlowTriever vs Catheter-Directed Thrombolysis in Intermediate Risk PTE

Pulmonary embolism (PE) continues to be the third cause of cardiovascular mortality. The current clinical guidelines recommend anticoagulation in intermediate risk patients presenting right...

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

TAVR and Atrial Fibrillation: What Anticoagulants Should We Use?

The prevalence of atrial fibrillation (AF) in TAVR patients ranges from 15 to 30%, depending on series. This arrhythmia has been associated to higher...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...